晚期非小细胞肺癌p53和ERCC1表达状态与顺铂为主的联合方案化疗的近期有效率的相关性研究  

Association of the Advanced Non-Small Cell Lung Cancer p53 and ERCC1 Expression Status with the Short-Term Effect of Combined Chemotherapy Revolved Around Cisplatin

作　　者：鞠放[1] 汪青[1] 清水汪[1] 孟蓉蓉[1] 王雅杰[1] 

机构地区：[1]上海第二军医大学附属长海医院肿瘤科,上海200433

出　　处：《现代生物医学进展》2012年第5期876-879,共4页Progress in Modern Biomedicine

基　　金：上海市科学技术委员会科研计划资助项目(06DZ19505);上海市卫生局科研计划项目(2009113)

摘　　要：目的:研究晚期非小细胞肺癌不同的p53和ERCC1表达状态与基于顺铂为主的姑息化疗近期有效率的相关性。方法:对经顺铂联合多西他赛或顺铂联合吉西他滨治疗的48例晚期非小细胞肺癌患者进行回顾性分析,利用既往免疫组化资料,观察基于顺铂为主的方案近期有效率(RR)的影响因素及化疗不良反应。结果:全组48例患者均完成至少两周期化疗,并行疗效评价。该组患者化疗的近期有效率为28例(58.3%),RR与不同的转移病灶部位(P=0.042)及病灶数目(P=0.034)有显著差异。该类方案的近期有效率与ERCC1状态(P=0.012)密切相关,而与p53表达状态(P=0.401)无关。毒性反应主要是骨髓抑制、脱发及消化道反应等。结论:晚期非小细胞肺癌ERCC1阴性患者较ERCC1阳性患者运用顺铂为主的联合方案化疗的近期有效率较高。ERCC1可能是顺铂疗效预测的敏感因子。p53的表达状态可能不是该类方案的疗效预测因子。Objective： This study is to explore the correlation of the advanced non-small cell lung cancer p53 and ERCCI express- ion status with the Short-term effect of combined chemotherapy revolved around cisplatin. Methods： After cisplatin combined docetaxol or cisplatin combined gemcitabine treatment, 48 advanced non-small cell lung cancer patients combined past Immunohistochemieal data were analyzed retrospectively. All patients with complete clinical and pathological data were observed as well as the Short-term effect impact factors of the chemotherapy and chemotherapy adverse. Results： The whole group 48 patients have completed at least two cycles of che motherapy, then completed efficacy evaluation. This group of patients of the chemotherapy recent response rate was 28 cases （58.3%）, RR with different metastatic sites （P=0.042） and the number of Metastasis （P = 0.028） were signifu^anfly different. The chemotherapy Short-term effect is closely related with ERCC1 expression status （P=0.034）and not with p53 expression ,status （P=0. 401 ）. Mainly toxicity symptoms were arrest of bone marrow, losing hair and archenteric indisposed. Conclusions： Advanced nonsmall cell lung cancer patients with ERCCl-negative have more effective Short-term effect of combined chemotherapy revolved around cisplatin than ERCC 1-positive p atients.ERCC 1 may predict the efficacy of c isplatin-sensitive fag tor, The expression of p53 may not be predictors of the efficacy ofcisplatin.

关 键 词：非小细胞肺癌 顺铂 ERCC1基因 P53 

分 类 号：R737.9[医药卫生—肿瘤]